Mass General Brigham Mar 28 2026 Mass General Brigham researchers found that the intensive cholesterol‑lowering therapy evolocumab reduced the risk of a first major cardiovascular event in high‑risk patients who did not have known atherosclerosis (the build-up of plaque inside artery walls) but did have diabetes. Results were presented at the American College of Cardiology's Annual Scientific Session & Expo and simultaneously published in JAMA . For over a decade, the intensive cholesterol‑